iiinova — where your digital self keeps evolving

Replies

Paul Thomas @pgtimmune.bsky.social · 24/11/2025

FLC is a rare, aggressive liver cancer lacking effective systemic therapies. Our vaccine targets the recurrent DNAJB1::PRKACA fusion, offering a universal neoantigen to drive anti-tumor immunity. www.nature.com/articles/s41...

nature.com

A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial - Nature Medicine

In this phase 1 trial, treatment of patients with fibrolamellar hepatocellular carcinoma with a therapeutic peptide vaccine targeting the fusion kinase DNAJB1–PRKACA, which is the driver of the diseas...

151

Paul Thomas @pgtimmune.bsky.social · 24/11/2025

In a first-of-its-kind trial, we combined the FLC vaccine with immune checkpoint blockade. Among patients with advanced disease, 75% mounted strong fusion-specific T cell responses, with 25% experiencing partial responses and durable progression-free survival.

120

Paul Thomas @pgtimmune.bsky.social · 24/11/2025

To truly interrogate immune responses at the clonal level, we needed unprecedented resolution. Enter TIRTL-Seq: an affordable, scalable platform generating millions of paired TCRαβ clones per experiment, enabling thorough quantification and tracking of T cell dynamics.

120